The role of chemotherapy in metastatic prostate cancer.
Curr Opin Urol
; 32(3): 292-301, 2022 05 01.
Article
in En
| MEDLINE
| ID: mdl-35552310
PURPOSE OF REVIEW: To summarize the role of chemotherapy and offer some guidance regarding the selection of chemotherapy in mPC. RECENT FINDINGS: Patients with mHSPC have varied prognoses with testosterone suppression alone (androgen deprivation therapy, ADT) and differential responses to docetaxel with ADT. Patients with de novo and metachronous high-volume disease have a robust survival benefit with the addition of docetaxel to hormonal therapies. Patients with synchronous low-volume disease have a more modest survival benefit from docetaxel and there is no evidence of survival benefit with docetaxel in patients with metachronous low-volume disease. Integration of biomarkers may refine treatment selection regardless of volume of disease. Docetaxel and cabazitaxel also impart an OS benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). The choice of chemotherapy in mCRPC depends on treatment received in mHSPC setting. Docetaxel remains the first line chemotherapy in castration-resistant patients who have not received it in mHSPC followed by cabazitaxel, otherwise cabazitaxel can be deployed without docetaxel retreatment. SUMMARY: Chemotherapy is a key class of therapy for selected patients with mHSPC and mCRPC.
Full text:
1
Database:
MEDLINE
Main subject:
Prostatic Neoplasms, Castration-Resistant
Type of study:
Guideline
/
Observational_studies
/
Prognostic_studies
Limits:
Humans
/
Male
Language:
En
Journal:
Curr Opin Urol
Journal subject:
UROLOGIA
Year:
2022
Type:
Article